...
首页> 外文期刊>Journal of Clinical Microbiology >Comparative Evaluation of the ExaVir Load Version 3 Reverse Transcriptase Assay for Measurement of Human Immunodeficiency Virus Type 1 Plasma Load
【24h】

Comparative Evaluation of the ExaVir Load Version 3 Reverse Transcriptase Assay for Measurement of Human Immunodeficiency Virus Type 1 Plasma Load

机译:ExaVir负荷版本3逆转录酶测定用于测量人类免疫缺陷病毒1型血浆负荷的比较评估

获取原文
           

摘要

In resource-limited settings, the virological monitoring of antiretroviral therapy is limited by high cost and the lack of infrastructure. The Cavidi ExaVir Load assay employs a simple and inexpensive enzyme-linked immunosorbent assay format to measure human immunodeficiency virus (HIV) reverse transcriptase activity, which correlates with plasma RNA load. The version 3 assay has been described as having improved precision and sensitivity. There are limited data on its performance relative to those of current real-time assays. Our objective was to compare HIV type 1 (HIV-1) RNA load measurement in plasma by ExaVir Load version 3 (designated ExaVir), Abbott M2000sp/M2000rt RealTime HIV-1 assay (designated RealTime), and Roche COBAS Ampliprep/COBAS TaqMan HIV-1 version 1 assay (designated TaqMan). Plasma from 119 patients (34 with subtype B infection, 85 with non-subtype B infection [A-H, CRF01, CRF02, CRF06, CRF12, CRF14, and complex]; 48 subjects were treatment experienced, 71 were naive) and serial dilutions of the second international standard (IS) were tested. Assay relationship and agreement were determined by linear regression, correlation analysis, and the Bland-Altman method. The ExaVir assay quantified 77/83 (92.8%) samples with viral loads of >2.3 log10 copies/ml by the molecular assays. Results were linearly associated and strongly correlated with RealTime and TaqMan measurements (R of 0.94 and 0.92, respectively) for both subtype B (R of 0.97 and 0.95, respectively) and non-subtype B (R of 0.93 and 0.91, respectively) samples. Mean differences were 0.28 and 0.18 log10 copies/ml in favor of the two molecular assays; 7/119 (5.9%) and 5/119 (4.2%) samples were outside the 95% level of agreement. ExaVir underquantified the IS by a mean of 0.2 (range, 0.0 to 0.5) log10 copies/ml. The ExaVir assay showed excellent concordance with real-time molecular assays, offering a suitable option for virological monitoring in settings with limited infrastructure.
机译:在资源有限的环境中,抗逆转录病毒疗法的病毒学监测受到高成本和缺乏基础设施的限制。 Cavidi ExaVir载量测定采用一种简单且便宜的酶联免疫吸附测定形式来测量人类免疫缺陷病毒(HIV)逆转录酶活性,该活性与血浆RNA载量相关。已经描述了版本3测定法具有提高的精度和灵敏度。相对于当前的实时测定,有关其性能的数据有限。我们的目标是比较ExaVir负荷版本3(指定为ExaVir),Abbott M2000sp / M2000rt RealTime HIV-1测定法(指定为RealTime)和Roche COBAS Ampliprep / COBAS TaqMan HIV在血浆中的HIV 1型(HIV-1)RNA负荷测量-1版本1分析(指定为TaqMan)。 119例患者的血浆(34例B型亚型感染,85例非B型亚型感染[AH,CRF01,CRF02,CRF06,CRF12,CRF14和复合体]; 48名有治疗经验的受试者,71名是幼稚的)和测试了第二国际标准(IS)。通过线性回归,相关分析和Bland-Altman方法确定测定的关系和一致性。 ExaVir分析通过分子分析定量了病毒载量> 2.3 log 10 拷贝/ ml的77/83(92.8%)个样品。对于B亚型( R 分别为0.97和0.95)和非B型,结果与RealTime和TaqMan测量值( R 分别为0.94和0.92)呈线性相关并高度相关。 -亚型B( R 分别为0.93和0.91)样本。两种分子测定的平均差异分别为0.28和0.18 log 10 拷贝/ ml。 7/119(5.9%)和5/119(4.2%)样本不在协议的95%水平。 ExaVir将IS量化的平均值为0.2(范围为0.0至0.5)log 10 个/ ml。 ExaVir测定与实时分子测定具有极好的一致性,为基础设施有限的环境中的病毒学监测提供了合适的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号